NK Bio

NK Bio was a South Korean biotechnology company specializing in the development of Natural Killer (NK) cell-based immunotherapies for the treatment of various cancers. The company focused on proprietary technologies for the large-scale expansion and activation of autologous NK cells, which were then re-infused into patients to target and destroy malignant cells. NK Bio gained significant attention for its NKM (NK cell-based immunotherapy) program, which reached clinical trials for indications such as lymphoma and solid tumors. However, the company faced significant financial and regulatory challenges, leading to its delisting from the KOSDAQ exchange and eventual cessation of operations.